Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRT-017
- Development stage
- Phase 1
- Lead developer
- Fosun Pharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
SRT-017 is an alpha-emitting radioligand therapy consisting of the alpha-emitting radionuclide actinium-225 ([225Ac]) conjugated to the prostate-specific membrane antigen (PSMA)-targeting ligand PSMA-0057. Developed by Chengdu Xingrui Jingxuan Biotechnology (a subsidiary of Fosun Pharma) in collaboration with Suzhou Ruihe Pharmaceutical Technology, SRT-017 is designed to selectively bind to PSMA-expressing prostate cancer cells. Upon binding, the high-energy, short-range alpha particles emitted by actinium-225 induce double-stranded DNA breaks, leading to tumor cell death while minimizing damage to surrounding healthy tissues. SRT-017 is being evaluated in clinical trials for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
- Other names
- actinium (225Ac) PSMA-0057actinium Ac 225 PSMA-0057[225]Ac-PSMA-0057 injection
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on SRT-017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRT-017.